Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor

go back to reference Zhang J, Xie B, Hashimoto K (2020) Current status of potential therapeutic candidates for the COVID-19 crisis. Brain Behav Immun 87:59–73PubMedPubMedCentralCrossRef Zhang J, Xie B, Hashimoto K (2020) Current status of potential therapeutic candidates for the COVID-19 crisis. Brain Behav Immun 87:59–73PubMedPubMedCentralCrossRef

go back to reference Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB (2020) Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA 323:1824–1836PubMed Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB (2020) Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA 323:1824–1836PubMed

go back to reference Zhao M, Zhang J, Li H, Luo Z, Ye J, Xu Y, Wang Z, Ye D, Liu J, Li D, Wang M, Wan J (2020) Recent progress of antiviral therapy for coronavirus disease 2019. Eur J Pharmacol 24:173646. https://doi.org/10.1016/j.ejphar.2020.173646CrossRef Zhao M, Zhang J, Li H, Luo Z, Ye J, Xu Y, Wang Z, Ye D, Liu J, Li D, Wang M, Wan J (2020) Recent progress of antiviral therapy for coronavirus disease 2019. Eur J Pharmacol 24:173646. https://​doi.​org/​10.​1016/​j.​ejphar.​2020.​173646CrossRef

go back to reference Abbasi J (2020) Existing drugs might treat COVID-19. JAMA 323:2239PubMed Abbasi J (2020) Existing drugs might treat COVID-19. JAMA 323:2239PubMed

go back to reference Abbasi J (2020) Drug repurposing study pinpoints potential COVID-19 antivirals. JAMA 324:928PubMed Abbasi J (2020) Drug repurposing study pinpoints potential COVID-19 antivirals. JAMA 324:928PubMed

go back to reference Touret F, Gilles M, Barral K, Nougairède A, van Helden J, Decroly E, de Lamballerie X, Coutard B (2020) In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Sci Rep 10:13093PubMedPubMedCentralCrossRef Touret F, Gilles M, Barral K, Nougairède A, van Helden J, Decroly E, de Lamballerie X, Coutard B (2020) In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Sci Rep 10:13093PubMedPubMedCentralCrossRef

go back to reference Wang X, Guan Y (2021) COVID-19 drug repurposing: a review of computational screening methods, clinical trials, and protein interaction assays. Med Res Rev 41:5–28PubMedCrossRef Wang X, Guan Y (2021) COVID-19 drug repurposing: a review of computational screening methods, clinical trials, and protein interaction assays. Med Res Rev 41:5–28PubMedCrossRef

go back to reference Zhou Y, Wang F, Tang J, Nussinov R, Cheng F (2020) Artificial intelligence in COVID-19 drug repurposing. Lancet 2:e667–e676 Zhou Y, Wang F, Tang J, Nussinov R, Cheng F (2020) Artificial intelligence in COVID-19 drug repurposing. Lancet 2:e667–e676

go back to reference Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, Liu C, Yang C (2020) Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun 87:18–22PubMedPubMedCentralCrossRef Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, Liu C, Yang C (2020) Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun 87:18–22PubMedPubMedCentralCrossRef

go back to reference Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, Zandi MS, Lewis G, David AS (2020) Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 7:611–627PubMedPubMedCentralCrossRef Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, Zandi MS, Lewis G, David AS (2020) Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 7:611–627PubMedPubMedCentralCrossRef

go back to reference Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, Kneen R, Defres S, Sejvar J, Solomon T (2020) Neurological associations of COVID-19. Lancet Neurol 19:767–783PubMedPubMedCentralCrossRef Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, Kneen R, Defres S, Sejvar J, Solomon T (2020) Neurological associations of COVID-19. Lancet Neurol 19:767–783PubMedPubMedCentralCrossRef

go back to reference Zhang J, Xu D, Xie B, Zhang Y, Huang H, Liu H, Chen H, Sun Y, Shang Y, Hashimoto K, Yuan S (2020) Poor-sleep is associated with slow recovery from lymphopenia and an increased need for ICU care in hospitalized patients with COVID-19: a retrospective cohort study. Brain Behav Immun 88:50–58PubMedPubMedCentralCrossRef Zhang J, Xu D, Xie B, Zhang Y, Huang H, Liu H, Chen H, Sun Y, Shang Y, Hashimoto K, Yuan S (2020) Poor-sleep is associated with slow recovery from lymphopenia and an increased need for ICU care in hospitalized patients with COVID-19: a retrospective cohort study. Brain Behav Immun 88:50–58PubMedPubMedCentralCrossRef

go back to reference Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S (2020) Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol 77:1018–1027PubMedPubMedCentralCrossRef Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S (2020) Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol 77:1018–1027PubMedPubMedCentralCrossRef

go back to reference Hashimoto K (2020) Risk of neuropsychiatric disorders in offspring of COVID-19-infected pregnant women and nutritional intervention. Eur Arch Psychiatry Clin Neurosci 2:1–3. https://doi.org/10.1007/s00406-020-01148-5CrossRef Hashimoto K (2020) Risk of neuropsychiatric disorders in offspring of COVID-19-infected pregnant women and nutritional intervention. Eur Arch Psychiatry Clin Neurosci 2:1–3. https://​doi.​org/​10.​1007/​s00406-020-01148-5CrossRef

go back to reference Zimmer A, Youngblood A, Adnane A, Miller BJ, Goldsmith DR (2020) Prenatal exposure to viral infection and neuropsychiatric disorders in offspring: a review of the literature and recommendations for the COVID-19 pandemic. Brain Behav Immun. https://doi.org/10.1016/j.bbi.2020.10.024CrossRefPubMedPubMedCentral Zimmer A, Youngblood A, Adnane A, Miller BJ, Goldsmith DR (2020) Prenatal exposure to viral infection and neuropsychiatric disorders in offspring: a review of the literature and recommendations for the COVID-19 pandemic. Brain Behav Immun. https://​doi.​org/​10.​1016/​j.​bbi.​2020.​10.​024CrossRefPubMedPubMedCentral

go back to reference Lenze E, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM (2020) Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19. A randomized clinical trial. JAMA 324:2292–2300PubMedPubMedCentralCrossRef Lenze E, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM (2020) Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19. A randomized clinical trial. JAMA 324:2292–2300PubMedPubMedCentralCrossRef

go back to reference Seymour CW, Bauchner H, Golub RM (2020) COVID-19 infection—preventing clinical deterioration. JAMA 324:2300PubMedCrossRef Seymour CW, Bauchner H, Golub RM (2020) COVID-19 infection—preventing clinical deterioration. JAMA 324:2300PubMedCrossRef

go back to reference Harrison AG, Lin T, Wang P (2020) Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trend Immunol 41:1100–1115CrossRef Harrison AG, Lin T, Wang P (2020) Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trend Immunol 41:1100–1115CrossRef

go back to reference Santerre M, Arjona SP, Allen CN, Shcherbik N, Sawaya BE (2020) Why do SARS-CoV-2 NSPs rush to the ER? J Neurol 1:1–10. https://doi.org/10.1007/s00415-020-10197-8CrossRef Santerre M, Arjona SP, Allen CN, Shcherbik N, Sawaya BE (2020) Why do SARS-CoV-2 NSPs rush to the ER? J Neurol 1:1–10. https://​doi.​org/​10.​1007/​s00415-020-10197-8CrossRef

go back to reference Banerjee A, Czinn SJ, Reiter RJ, Blanchard TG (2020) Crosstalk between endoplasmic reticulum stress and anti-viral activities: a novel therapeutic target for COVID-19. Life Sci 255:117842PubMedPubMedCentralCrossRef Banerjee A, Czinn SJ, Reiter RJ, Blanchard TG (2020) Crosstalk between endoplasmic reticulum stress and anti-viral activities: a novel therapeutic target for COVID-19. Life Sci 255:117842PubMedPubMedCentralCrossRef

go back to reference Aoe T (2020) Pathological aspects of COVID-19 as a conformational disease and the use of pharmacological chaperones as a potential therapeutic strategy. Front Pharmacol 11:1096CrossRef Aoe T (2020) Pathological aspects of COVID-19 as a conformational disease and the use of pharmacological chaperones as a potential therapeutic strategy. Front Pharmacol 11:1096CrossRef

go back to reference Köseler A, Sabirli R, Gören T, Türkçüer I, Kurt Ö (2020) Endoplasmic reticulum stress markers in SARS-COV-2 infection and pneumonia: case control study. In Vivo 34:1645–1650PubMedPubMedCentralCrossRef Köseler A, Sabirli R, Gören T, Türkçüer I, Kurt Ö (2020) Endoplasmic reticulum stress markers in SARS-COV-2 infection and pneumonia: case control study. In Vivo 34:1645–1650PubMedPubMedCentralCrossRef

go back to reference Sureda A, Alizadeh J, Nabavi SF, Berindan-Neagoe I, Cismaru CA, Jeandet P, Łos MJ, Clementi E, Nabavi SM, Ghavami S (2020) Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management? Eur J Pharmacol 882:173288PubMedPubMedCentralCrossRef Sureda A, Alizadeh J, Nabavi SF, Berindan-Neagoe I, Cismaru CA, Jeandet P, Łos MJ, Clementi E, Nabavi SM, Ghavami S (2020) Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management? Eur J Pharmacol 882:173288PubMedPubMedCentralCrossRef

go back to reference Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE (1976) The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197:517–532PubMed Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE (1976) The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197:517–532PubMed

go back to reference Su TP (1982) Evidence for sigma opioid receptor: binding of [3H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain. J Pharmacol Exp Ther 223:284–290PubMed Su TP (1982) Evidence for sigma opioid receptor: binding of [³H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain. J Pharmacol Exp Ther 223:284–290PubMed

go back to reference Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, Glossmann H (1997) Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci USA 93:8072–8077CrossRef Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, Glossmann H (1997) Purification, molecular cloning, and expression of the mammalian sigma₁-binding site. Proc Natl Acad Sci USA 93:8072–8077CrossRef

go back to reference Hayashi T, Su TP (2007) Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Cell 131:596–610PubMedCrossRef Hayashi T, Su TP (2007) Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca²⁺ signaling and cell survival. Cell 131:596–610PubMedCrossRef

go back to reference Hayashi T, Tsai SY, Mori T, Fujimoto M, Su TP (2011) Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders. Expert Opin Ther Targets 15:557–577PubMedCrossRef Hayashi T, Tsai SY, Mori T, Fujimoto M, Su TP (2011) Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders. Expert Opin Ther Targets 15:557–577PubMedCrossRef

go back to reference Alon A, Schmidt HR, Wood MD, Sahn JJ, Martin SF, Kruse AC (2017) Identification of the gene that codes for the σ2 receptor. Proc Natl Acad Sci USA 114:7160–7165PubMedPubMedCentralCrossRef Alon A, Schmidt HR, Wood MD, Sahn JJ, Martin SF, Kruse AC (2017) Identification of the gene that codes for the σ₂ receptor. Proc Natl Acad Sci USA 114:7160–7165PubMedPubMedCentralCrossRef

go back to reference Hashimoto K, Ishiwata K (2006) Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des 12:3857–3876PubMed Hashimoto K, Ishiwata K (2006) Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des 12:3857–3876PubMed

go back to reference Hayashi T, Su TP (2008) An update on the development of drugs for neuropsychiatric disorders: focusing on the sigma-1 receptor ligand. Expert Opin Ther Targets 12:45–58PubMedCrossRef Hayashi T, Su TP (2008) An update on the development of drugs for neuropsychiatric disorders: focusing on the sigma-1 receptor ligand. Expert Opin Ther Targets 12:45–58PubMedCrossRef

go back to reference Hashimoto K (2009) Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Cent Nerv Syst Agents Med Chem 9:197–204PubMedCrossRef Hashimoto K (2009) Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Cent Nerv Syst Agents Med Chem 9:197–204PubMedCrossRef

go back to reference Niitsu T, Iyo M, Hashimoto K (2012) Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases. Curr Pham Des 18:875–883CrossRef Niitsu T, Iyo M, Hashimoto K (2012) Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases. Curr Pham Des 18:875–883CrossRef

go back to reference Hashimoto K (2013) Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog Neurobiol 100:15–29PubMedCrossRef Hashimoto K (2013) Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog Neurobiol 100:15–29PubMedCrossRef

go back to reference Hashimoto K (2015) Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication. J Pharmacol Sci 127:6–9PubMedCrossRef Hashimoto K (2015) Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication. J Pharmacol Sci 127:6–9PubMedCrossRef

go back to reference Albayrak Y, Hashimoto K (2017) Sigma-1 receptor agonists and their clinical implications in neuropsychiatric disorders. Adv Exp Med Biol 964:153–161PubMedCrossRef Albayrak Y, Hashimoto K (2017) Sigma-1 receptor agonists and their clinical implications in neuropsychiatric disorders. Adv Exp Med Biol 964:153–161PubMedCrossRef

go back to reference Schmidt HR, Kruse AC (2019) The molecular function of σ receptors: past, present, and future. Trends Pharmacol Sci 40:636–654PubMedPubMedCentralCrossRef Schmidt HR, Kruse AC (2019) The molecular function of σ receptors: past, present, and future. Trends Pharmacol Sci 40:636–654PubMedPubMedCentralCrossRef

go back to reference Su TP (2019) Non-canonical targets mediating the action of drugs of abuse: cocaine at the sigma-1 receptor as an example. Front Neurosci 13:761PubMedPubMedCentralCrossRef Su TP (2019) Non-canonical targets mediating the action of drugs of abuse: cocaine at the sigma-1 receptor as an example. Front Neurosci 13:761PubMedPubMedCentralCrossRef

go back to reference Maurice T (2020) Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders. Expert Opin Drug Discov 27:1–17. https://doi.org/10.1080/17460441.2021.1838483CrossRef Maurice T (2020) Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders. Expert Opin Drug Discov 27:1–17. https://​doi.​org/​10.​1080/​17460441.​2021.​1838483CrossRef

go back to reference Couly S, Goguadze N, Yasui Y, Kimura Y, Wang SM, Sharikadze N, Wu HE, Su TP (2020) Knocking out sigma-1 receptors reveals diverse health problems. Cell Mol Neurobiol. https://doi.org/10.1007/s10571-020-00983-3CrossRefPubMed Couly S, Goguadze N, Yasui Y, Kimura Y, Wang SM, Sharikadze N, Wu HE, Su TP (2020) Knocking out sigma-1 receptors reveals diverse health problems. Cell Mol Neurobiol. https://​doi.​org/​10.​1007/​s10571-020-00983-3CrossRefPubMed

go back to reference Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O’Meara MJ, Rezelj VV, Guo JZ, Swaney DL, Tummino TA, Hüttenhain R, Kaake RM, Richards AL, Tutuncuoglu B, Foussard H, Batra J, Haas K, Modak M, Kim M, Haas P, Polacco BJ, Braberg H, Fabius JM, Eckhardt M, Soucheray M, Bennett MJ, Cakir M, McGregor MJ, Li Q, Meyer B, Roesch F, Vallet T, Mac Kain A, Miorin L, Moreno E, Naing ZZC, Zhou Y, Peng S, Shi Y, Zhang Z, Shen W, Kirby IT, Melnyk JE, Chorba JS, Lou K, Dai SA, Barrio-Hernandez I, Memon D, Hernandez-Armenta C, Lyu J, Mathy CJP, Perica T, Pilla KB, Ganesan SJ, Saltzberg DJ, Rakesh R, Liu X, Rosenthal SB, Calviello L, Venkataramanan S, Liboy-Lugo J, Lin Y, Huang XP, Liu Y, Wankowicz SA, Bohn M, Safari M, Ugur FS, Koh C, Savar NS, Tran QD, Shengjuler D, Fletcher SJ, O’Neal MC, Cai Y, Chang JCJ, Broadhurst DJ, Klippsten S, Sharp PP, Wenzell NA, Kuzuoglu-Ozturk D, Wang HY, Trenker R, Young JM, Cavero DA, Hiatt J, Roth TL, Rathore U, Subramanian A, Noack J, Hubert M, Stroud RM, Frankel AD, Rosenberg OS, Verba KA, Agard DA, Ott M, Emerman M, Jura N, von Zastrow M, Verdin E, Ashworth A, Schwartz O, d’Enfert C, Mukherjee S, Jacobson M, Malik HS, Fujimori DG, Ideker T, Craik CS, Floor SN, Fraser JS, Gross JD, Sali A, Roth BL, Ruggero D, Taunton J, Kortemme T, Beltrao P, Vignuzzi M, García-Sastre A, Shokat KM, Shoichet BK, Krogan NJ (2020) A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583:459–468PubMedPubMedCentralCrossRef Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O’Meara MJ, Rezelj VV, Guo JZ, Swaney DL, Tummino TA, Hüttenhain R, Kaake RM, Richards AL, Tutuncuoglu B, Foussard H, Batra J, Haas K, Modak M, Kim M, Haas P, Polacco BJ, Braberg H, Fabius JM, Eckhardt M, Soucheray M, Bennett MJ, Cakir M, McGregor MJ, Li Q, Meyer B, Roesch F, Vallet T, Mac Kain A, Miorin L, Moreno E, Naing ZZC, Zhou Y, Peng S, Shi Y, Zhang Z, Shen W, Kirby IT, Melnyk JE, Chorba JS, Lou K, Dai SA, Barrio-Hernandez I, Memon D, Hernandez-Armenta C, Lyu J, Mathy CJP, Perica T, Pilla KB, Ganesan SJ, Saltzberg DJ, Rakesh R, Liu X, Rosenthal SB, Calviello L, Venkataramanan S, Liboy-Lugo J, Lin Y, Huang XP, Liu Y, Wankowicz SA, Bohn M, Safari M, Ugur FS, Koh C, Savar NS, Tran QD, Shengjuler D, Fletcher SJ, O’Neal MC, Cai Y, Chang JCJ, Broadhurst DJ, Klippsten S, Sharp PP, Wenzell NA, Kuzuoglu-Ozturk D, Wang HY, Trenker R, Young JM, Cavero DA, Hiatt J, Roth TL, Rathore U, Subramanian A, Noack J, Hubert M, Stroud RM, Frankel AD, Rosenberg OS, Verba KA, Agard DA, Ott M, Emerman M, Jura N, von Zastrow M, Verdin E, Ashworth A, Schwartz O, d’Enfert C, Mukherjee S, Jacobson M, Malik HS, Fujimori DG, Ideker T, Craik CS, Floor SN, Fraser JS, Gross JD, Sali A, Roth BL, Ruggero D, Taunton J, Kortemme T, Beltrao P, Vignuzzi M, García-Sastre A, Shokat KM, Shoichet BK, Krogan NJ (2020) A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583:459–468PubMedPubMedCentralCrossRef

go back to reference Gordon DE, Hiatt J, Bouhaddou M, Rezelj VV, Ulferts S, Braberg H, Jureka AS, Obernier K, Guo JZ, Batra J, Kaake RM, Weckstein AR, Owens TW, Gupta M, Pourmal S, Titus EW, Cakir M, Soucheray M, McGregor M, Cakir Z, Jang G, O’Meara MJ, Tummino TA, Zhang Z, Foussard H, Rojc A, Zhou Y, Kuchenov D, Hüttenhain R, Xu J, Eckhardt M, Swaney DL, Fabius JM, Ummadi M, Tutuncuoglu B, Rathore U, Modak M, Haas P, Haas KM, Naing ZZC, Pulido EH, Shi Y, Barrio-Hernandez I, Memon D, Petsalaki E, Dunham A, Marrero MC, Burke D, Koh C, Vallet T, Silvas JA, Azumaya CM, Billesbølle C, Brilot AF, Campbell MG, Diallo A, Dickinson MS, Diwanji D, Herrera N, Hoppe N, Kratochvil HT, Liu Y, Merz GE, Moritz M, Nguyen HC, Nowotny C, Puchades C, Rizo AN, Schulze-Gahmen U, Smith AM, Sun M, Young ID, Zhao J, Asarnow D, Biel J, Bowen A, Braxton JR, Chen J, Chio CM, Chio US, Deshpande I, Doan L, Faust B, Flores S, Jin M, Kim K, Lam VL, Li F, Li J, Li YL, Li Y, Liu X, Lo M, Lopez KE, Melo AA, Moss FR 3rd, Nguyen P, Paulino J, Pawar KI, Peters JK, Pospiech TH Jr, Safari M, Sangwan S, Schaefer K, Thomas PV, Thwin AC, Trenker R, Tse E, Tsui TKM, Wang F, Whitis N, Yu Z, Zhang K, Zhang Y, Zhou F, Saltzberg D, QCRG Structural Biology Consortium, Hodder AJ, Shun-Shion AS, Williams DM, White KM, Rosales R, Kehrer T, Miorin L, Moreno E, Patel AH, Rihn S, Khalid MM, Vallejo-Gracia A, Fozouni P, Simoneau CR, Roth TL, Wu D, Karim MA, Ghoussaini M, Dunham I, Berardi F, Weigang S, Chazal M, Park J, Logue J, McGrath M, Weston S, Haupt R, Hastie CJ, Elliott M, Brown F, Burness KA, Reid E, Dorward M, Johnson C, Wilkinson SG, Geyer A, Giesel DM, Baillie C, Raggett S, Leech H, Toth R, Goodman N, Keough KC, Lind AL, Zoonomia Consortium, Klesh RJ, Hemphill KR, Carlson-Stevermer J, Oki J, Holden K, Maures T, Pollard KS, Sali A, Agard DA, Cheng Y, Fraser JS, Frost A, Jura N, Kortemme T, Manglik A, Southworth DR, Stroud RM, Alessi DR, Davies P, Frieman MB, Ideker T, Abate C, Jouvenet N, Kochs G, Shoichet B, Ott M, Palmarini M, Shokat KM, García-Sastre A, Rassen JA, Grosse R, Rosenberg OS, Verba KA, Basler CF, Vignuzzi M, Peden AA, Beltrao P, Krogan NJ (2020) Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science 370:eabe9403PubMedPubMedCentralCrossRef Gordon DE, Hiatt J, Bouhaddou M, Rezelj VV, Ulferts S, Braberg H, Jureka AS, Obernier K, Guo JZ, Batra J, Kaake RM, Weckstein AR, Owens TW, Gupta M, Pourmal S, Titus EW, Cakir M, Soucheray M, McGregor M, Cakir Z, Jang G, O’Meara MJ, Tummino TA, Zhang Z, Foussard H, Rojc A, Zhou Y, Kuchenov D, Hüttenhain R, Xu J, Eckhardt M, Swaney DL, Fabius JM, Ummadi M, Tutuncuoglu B, Rathore U, Modak M, Haas P, Haas KM, Naing ZZC, Pulido EH, Shi Y, Barrio-Hernandez I, Memon D, Petsalaki E, Dunham A, Marrero MC, Burke D, Koh C, Vallet T, Silvas JA, Azumaya CM, Billesbølle C, Brilot AF, Campbell MG, Diallo A, Dickinson MS, Diwanji D, Herrera N, Hoppe N, Kratochvil HT, Liu Y, Merz GE, Moritz M, Nguyen HC, Nowotny C, Puchades C, Rizo AN, Schulze-Gahmen U, Smith AM, Sun M, Young ID, Zhao J, Asarnow D, Biel J, Bowen A, Braxton JR, Chen J, Chio CM, Chio US, Deshpande I, Doan L, Faust B, Flores S, Jin M, Kim K, Lam VL, Li F, Li J, Li YL, Li Y, Liu X, Lo M, Lopez KE, Melo AA, Moss FR 3rd, Nguyen P, Paulino J, Pawar KI, Peters JK, Pospiech TH Jr, Safari M, Sangwan S, Schaefer K, Thomas PV, Thwin AC, Trenker R, Tse E, Tsui TKM, Wang F, Whitis N, Yu Z, Zhang K, Zhang Y, Zhou F, Saltzberg D, QCRG Structural Biology Consortium, Hodder AJ, Shun-Shion AS, Williams DM, White KM, Rosales R, Kehrer T, Miorin L, Moreno E, Patel AH, Rihn S, Khalid MM, Vallejo-Gracia A, Fozouni P, Simoneau CR, Roth TL, Wu D, Karim MA, Ghoussaini M, Dunham I, Berardi F, Weigang S, Chazal M, Park J, Logue J, McGrath M, Weston S, Haupt R, Hastie CJ, Elliott M, Brown F, Burness KA, Reid E, Dorward M, Johnson C, Wilkinson SG, Geyer A, Giesel DM, Baillie C, Raggett S, Leech H, Toth R, Goodman N, Keough KC, Lind AL, Zoonomia Consortium, Klesh RJ, Hemphill KR, Carlson-Stevermer J, Oki J, Holden K, Maures T, Pollard KS, Sali A, Agard DA, Cheng Y, Fraser JS, Frost A, Jura N, Kortemme T, Manglik A, Southworth DR, Stroud RM, Alessi DR, Davies P, Frieman MB, Ideker T, Abate C, Jouvenet N, Kochs G, Shoichet B, Ott M, Palmarini M, Shokat KM, García-Sastre A, Rassen JA, Grosse R, Rosenberg OS, Verba KA, Basler CF, Vignuzzi M, Peden AA, Beltrao P, Krogan NJ (2020) Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science 370:eabe9403PubMedPubMedCentralCrossRef

go back to reference Tam SW, Cook L (1984) σ opiates and certain antipsychotic drugs mutually inhibit (+)-[3H]SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes. Proc Natl Acad Sci USA 81:5618–5621PubMedPubMedCentralCrossRef Tam SW, Cook L (1984) σ opiates and certain antipsychotic drugs mutually inhibit (+)-[³H]SKF 10,047 and [³H]haloperidol binding in guinea pig brain membranes. Proc Natl Acad Sci USA 81:5618–5621PubMedPubMedCentralCrossRef

go back to reference Harrison C (2020) Drug researchers pursue new lines of attack against COVID-19. Nat Biotechnol 38:655–664CrossRef Harrison C (2020) Drug researchers pursue new lines of attack against COVID-19. Nat Biotechnol 38:655–664CrossRef

go back to reference Iyo M, Tadokoro S, Kanahara N, Hashimoto T, Niitsu T, Watanabe H, Hashimoto K (2013) Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J Clin Psychopharmacol 33:398–404PubMedCrossRef Iyo M, Tadokoro S, Kanahara N, Hashimoto T, Niitsu T, Watanabe H, Hashimoto K (2013) Optimal extent of dopamine D₂ receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J Clin Psychopharmacol 33:398–404PubMedCrossRef

go back to reference Okuyama S, Imagawa Y, Ogawa S, Araki H, Ajima A, Tanaka M, Muramatsu M, Nakazato A, Yamaguchi K, Yoshida M, Otomo S (1993) NE-100, a novel sigma receptor ligand: in vivo tests. Life Sci 53:PL285–PL290PubMedCrossRef Okuyama S, Imagawa Y, Ogawa S, Araki H, Ajima A, Tanaka M, Muramatsu M, Nakazato A, Yamaguchi K, Yoshida M, Otomo S (1993) NE-100, a novel sigma receptor ligand: in vivo tests. Life Sci 53:PL285–PL290PubMedCrossRef

go back to reference Narita N, Hashimoto K, Tomitaka S, Minabe Y (1996) Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 307:117–119PubMedCrossRef Narita N, Hashimoto K, Tomitaka S, Minabe Y (1996) Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 307:117–119PubMedCrossRef

go back to reference Ishima T, Fujita Y, Hashimoto K (2014) Interactions of new antidepressants with sigma-1 receptor chaperons and their potentiation of neurite outgrowth in PC12 cells. Eur J Pharmacol 727:167–173PubMedCrossRef Ishima T, Fujita Y, Hashimoto K (2014) Interactions of new antidepressants with sigma-1 receptor chaperons and their potentiation of neurite outgrowth in PC12 cells. Eur J Pharmacol 727:167–173PubMedCrossRef

go back to reference Nishimura T, Ishima T, Iyo M, Hashimoto K (2008) Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS ONE 3:e2558PubMedPubMedCentralCrossRef Nishimura T, Ishima T, Iyo M, Hashimoto K (2008) Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP₃ receptors and cellular signaling pathways. PLoS ONE 3:e2558PubMedPubMedCentralCrossRef

go back to reference Hashimoto K, Fujita Y, Iyo M (2007) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology 32:514–521PubMedCrossRef Hashimoto K, Fujita Y, Iyo M (2007) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology 32:514–521PubMedCrossRef

go back to reference Ishima T, Fujita Y, Kohno M, Kunitachi S, Horio M, Takatsu Y, Minase T, Iyo M, Hashimoto K (2009) Improvement of phencyclidine-induced cognitive deficits in mice by subsequent subchronic administration of fluvoxamine, but not sertraline. Open Clin Chem J 2:7–11CrossRef Ishima T, Fujita Y, Kohno M, Kunitachi S, Horio M, Takatsu Y, Minase T, Iyo M, Hashimoto K (2009) Improvement of phencyclidine-induced cognitive deficits in mice by subsequent subchronic administration of fluvoxamine, but not sertraline. Open Clin Chem J 2:7–11CrossRef

go back to reference Iyo M, Shirayama Y, Watanabe H, Fujisaki M, Miyatake R, Fukami G, Shiina A, Nakazato M, Shiraishi T, Ookami T, Hashimoto K (2008) Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32:1072–1073PubMedCrossRef Iyo M, Shirayama Y, Watanabe H, Fujisaki M, Miyatake R, Fukami G, Shiina A, Nakazato M, Shiraishi T, Ookami T, Hashimoto K (2008) Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32:1072–1073PubMedCrossRef

go back to reference Niitsu T, Shirayama Y, Fujisaki M, Hashimoto K, Iyo M (2010) Fluvoxamine improved cognitive impairments in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 34:1345–1346PubMedCrossRef Niitsu T, Shirayama Y, Fujisaki M, Hashimoto K, Iyo M (2010) Fluvoxamine improved cognitive impairments in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 34:1345–1346PubMedCrossRef

go back to reference Niitsu T, Fujisaki M, Shiina A, Yoshida T, Hasegawa T, Kanahara N, Hashimoto T, Shiraishi T, Fukami G, Nakazato M, Shirayama Y, Hashimoto K, Iyo M (2012) A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study. J Clin Psychopharmacol 32:593–601PubMedCrossRef Niitsu T, Fujisaki M, Shiina A, Yoshida T, Hasegawa T, Kanahara N, Hashimoto T, Shiraishi T, Fukami G, Nakazato M, Shirayama Y, Hashimoto K, Iyo M (2012) A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study. J Clin Psychopharmacol 32:593–601PubMedCrossRef

go back to reference Kishi T, Hirota T, Iwata N (2013) Add-on fluvoxamine treatment for schizophrenia: an updated meta-analysis of randomized controlled trials. Eur Arch psychiatry Clin Neurosci 263:633–641PubMedCrossRef Kishi T, Hirota T, Iwata N (2013) Add-on fluvoxamine treatment for schizophrenia: an updated meta-analysis of randomized controlled trials. Eur Arch psychiatry Clin Neurosci 263:633–641PubMedCrossRef

go back to reference Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, Oda K, Miyatake R, Fujisaki M, Shimizu E, Shirayama Y, Iyo M, Hashimoto K (2007) High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503. Biol Psychiatry 62:878–883PubMedCrossRef Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, Oda K, Miyatake R, Fujisaki M, Shimizu E, Shirayama Y, Iyo M, Hashimoto K (2007) High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [¹¹C]SA4503. Biol Psychiatry 62:878–883PubMedCrossRef

go back to reference Hindmarch I, Hashimoto K (2010) Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum Psychopharmacol 25:193–200PubMedCrossRef Hindmarch I, Hashimoto K (2010) Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum Psychopharmacol 25:193–200PubMedCrossRef

go back to reference Furuse T, Hashimoto K (2010) Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases. Ann Gen Psychiatry 9:18PubMedPubMedCentralCrossRef Furuse T, Hashimoto K (2010) Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases. Ann Gen Psychiatry 9:18PubMedPubMedCentralCrossRef

go back to reference Rosen DA, Seki SM, Fernández-Castañeda A, Beiter RM, Eccles JD, Woodfolk JA, Gaultier A (2019) Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med 11:eaau5266PubMedPubMedCentralCrossRef Rosen DA, Seki SM, Fernández-Castañeda A, Beiter RM, Eccles JD, Woodfolk JA, Gaultier A (2019) Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med 11:eaau5266PubMedPubMedCentralCrossRef

go back to reference Kato K, Hayako H, Ishihara Y, Marui S, Iwane M, Miyamoto M (1999) TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons. Neurosci Lett 260:5–8PubMedCrossRef Kato K, Hayako H, Ishihara Y, Marui S, Iwane M, Miyamoto M (1999) TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons. Neurosci Lett 260:5–8PubMedCrossRef

go back to reference Ishima T, Nishimura T, Iyo M, Hashimoto K (2008) Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: role of sigma-1 receptors and IP3 receptors. Prog Neuropsychopharmacol Biol Psychiatry 32:1656–1659PubMedCrossRef Ishima T, Nishimura T, Iyo M, Hashimoto K (2008) Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: role of sigma-1 receptors and IP3 receptors. Prog Neuropsychopharmacol Biol Psychiatry 32:1656–1659PubMedCrossRef

go back to reference Kunitachi S, Fujita Y, Ishima T, Kohno M, Horio M, Tanibuchi Y, Shirayama Y, Iyo M, Hashimoto K (2009) Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: role of sigma-1 receptors. Brain Res 1279:189–196PubMedCrossRef Kunitachi S, Fujita Y, Ishima T, Kohno M, Horio M, Tanibuchi Y, Shirayama Y, Iyo M, Hashimoto K (2009) Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: role of sigma-1 receptors. Brain Res 1279:189–196PubMedCrossRef

go back to reference Ishikawa M, Sakata M, Ishii K, Kimura Y, Oda K, Toyohara J, Wu J, Ishiwata K, Iyo M, Hashimoto K (2009) High occupancy of sigma1 receptors in the human brain after single oral administration of donepezil: a positron emission tomography study using [11C]SA4503. Int J Neuropsychopharmacol 12:1127–1131PubMedCrossRef Ishikawa M, Sakata M, Ishii K, Kimura Y, Oda K, Toyohara J, Wu J, Ishiwata K, Iyo M, Hashimoto K (2009) High occupancy of sigma1 receptors in the human brain after single oral administration of donepezil: a positron emission tomography study using [¹¹C]SA4503. Int J Neuropsychopharmacol 12:1127–1131PubMedCrossRef

go back to reference Hashimoto K, London ED (1993) Further characterization of [3H]ifenprodil binding to sigma receptors in rat brain. Eur J Pharmacol 236:159–163PubMedCrossRef Hashimoto K, London ED (1993) Further characterization of [³H]ifenprodil binding to sigma receptors in rat brain. Eur J Pharmacol 236:159–163PubMedCrossRef

go back to reference Hashimoto K, Mantione CR, Spada MR, Neumeyer JL, London ED (1994) Further characterization of [3H]ifenprodil binding in rat brain. Eur J Pharmacol 266:67–77PubMedCrossRef Hashimoto K, Mantione CR, Spada MR, Neumeyer JL, London ED (1994) Further characterization of [³H]ifenprodil binding in rat brain. Eur J Pharmacol 266:67–77PubMedCrossRef

go back to reference Hashimoto K, London ED (1995) Interactions of erythro-ifenprodil, threo-ifenprodil, erythro-iodoifenprodil, and eliprodil with subtypes of sigma receptors. Eur J Pharmacol 273:307–310PubMedCrossRef Hashimoto K, London ED (1995) Interactions of erythro-ifenprodil, threo-ifenprodil, erythro-iodoifenprodil, and eliprodil with subtypes of sigma receptors. Eur J Pharmacol 273:307–310PubMedCrossRef

go back to reference Ishima T, Hashimoto K (2012) Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by ifenprodil: role of sigma-1 receptor and IP3 receptor. PLoS ONE 7:e37989PubMedPubMedCentralCrossRef Ishima T, Hashimoto K (2012) Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by ifenprodil: role of sigma-1 receptor and IP₃ receptor. PLoS ONE 7:e37989PubMedPubMedCentralCrossRef

go back to reference Kishimoto A, Kaneko M, Gotoh Y, Hashimoto K (2012) Ifenprodil for the treatment of flashbacks in female posttraumatic stress disorder patients with a history of childhood sexual abuse. Biol Psychiatry 71:e7–e8PubMedCrossRef Kishimoto A, Kaneko M, Gotoh Y, Hashimoto K (2012) Ifenprodil for the treatment of flashbacks in female posttraumatic stress disorder patients with a history of childhood sexual abuse. Biol Psychiatry 71:e7–e8PubMedCrossRef

go back to reference Sasaki T, Hashimoto K, Okawada K, Tone J, Machizawa A, Tano A, Nakazato M, Iyo M (2013) Ifenprodil for the treatment of flashbacks in adolescent female posttraumatic stress disorder patients with a history of abuse. Psychother Psychosom 82:344–345PubMedCrossRef Sasaki T, Hashimoto K, Okawada K, Tone J, Machizawa A, Tano A, Nakazato M, Iyo M (2013) Ifenprodil for the treatment of flashbacks in adolescent female posttraumatic stress disorder patients with a history of abuse. Psychother Psychosom 82:344–345PubMedCrossRef

go back to reference Hashimoto K, Sasaki T, Kishimoto A (2013) Old drug ifenprodil, new hope for PTSD with a history of childhood abuse. Psychopharmacology 227:375–376PubMedCrossRef Hashimoto K, Sasaki T, Kishimoto A (2013) Old drug ifenprodil, new hope for PTSD with a history of childhood abuse. Psychopharmacology 227:375–376PubMedCrossRef

go back to reference Matsuno K, Nakazawa M, Okamoto K, Kawashima Y, Mita S (1996) Binding properties of SA4503, a novel and selective sigma-1 receptor agonist. Eur J Pharmacol 306:271–279PubMedCrossRef Matsuno K, Nakazawa M, Okamoto K, Kawashima Y, Mita S (1996) Binding properties of SA4503, a novel and selective sigma-1 receptor agonist. Eur J Pharmacol 306:271–279PubMedCrossRef

go back to reference Ruscher K, Shamloo M, Rickhag M, Ladunga I, Soriano L, Gisselsson L, Toresson H, Ruslim-Litrus L, Oksenberg D, Urfer R, Johansson BB, Nikolich K, Wieloch T (2011) The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke. Brain 134(Pt 3):732–746PubMedCrossRef Ruscher K, Shamloo M, Rickhag M, Ladunga I, Soriano L, Gisselsson L, Toresson H, Ruslim-Litrus L, Oksenberg D, Urfer R, Johansson BB, Nikolich K, Wieloch T (2011) The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke. Brain 134(Pt 3):732–746PubMedCrossRef

go back to reference Urfer R, Moebius HJ, Skoloudik D, Santamarina E, Sato W, Mita S, Muir KW, Cutamesine Stroke Recovery Study Group (2014) Phase II trial of the Sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke. Stroke 45:3304–3310PubMedCrossRef Urfer R, Moebius HJ, Skoloudik D, Santamarina E, Sato W, Mita S, Muir KW, Cutamesine Stroke Recovery Study Group (2014) Phase II trial of the Sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke. Stroke 45:3304–3310PubMedCrossRef

go back to reference Vela JM (2020) Repurposing sigma-1 receptor ligands for COVID-19 therapy? Front Pharmacol 11:582310PubMedPubMedCentralCrossRef Vela JM (2020) Repurposing sigma-1 receptor ligands for COVID-19 therapy? Front Pharmacol 11:582310PubMedPubMedCentralCrossRef

go back to reference Domino EF (2010) Taming the ketamine tiger. 1965. Anesthesiology 113:678–684PubMedCrossRef Domino EF (2010) Taming the ketamine tiger. 1965. Anesthesiology 113:678–684PubMedCrossRef

go back to reference Zhang K, Hashimoto K (2020) An update on ketamine and its two enantiomers as rapid-acting antidepressants. Expert Opin Neurother 19:83–92CrossRef Zhang K, Hashimoto K (2020) An update on ketamine and its two enantiomers as rapid-acting antidepressants. Expert Opin Neurother 19:83–92CrossRef

go back to reference Hashimoto K (2019) Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective. Psychiatry Clin Neurosci 73:613–627PubMedPubMedCentralCrossRef Hashimoto K (2019) Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective. Psychiatry Clin Neurosci 73:613–627PubMedPubMedCentralCrossRef

go back to reference Hashimoto K (2020) Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine. Biochem Pharmacol 177:113935PubMedCrossRef Hashimoto K (2020) Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine. Biochem Pharmacol 177:113935PubMedCrossRef

go back to reference Robson MJ, Elliott M, Seminerio MJ, Matsumoto RR (2012) Evaluation of sigma (σ) receptors in the antidepressant-like effects of ketamine in vitro and in vivo. Eur Neuropsychopharmacol 22:308–317PubMedCrossRef Robson MJ, Elliott M, Seminerio MJ, Matsumoto RR (2012) Evaluation of sigma (σ) receptors in the antidepressant-like effects of ketamine in vitro and in vivo. Eur Neuropsychopharmacol 22:308–317PubMedCrossRef

go back to reference Yang JJ, Wang N, Yang C, Shi JY, Yu HY, Hashimoto K (2015) Serum interleukin-6 is a predictive biomarker for ketamine’s antidepressant effect in treatment-resistant patients with major depression. Biol Psychiatry 77:e19–e20PubMedCrossRef Yang JJ, Wang N, Yang C, Shi JY, Yu HY, Hashimoto K (2015) Serum interleukin-6 is a predictive biomarker for ketamine’s antidepressant effect in treatment-resistant patients with major depression. Biol Psychiatry 77:e19–e20PubMedCrossRef

go back to reference Ortoleva J (2020) Consider adjunctive ketamine in mechanically ventilated coronavirus disease-2019 patients. J Cardiothorac Vasc Anesth 34:2580PubMedPubMedCentralCrossRef Ortoleva J (2020) Consider adjunctive ketamine in mechanically ventilated coronavirus disease-2019 patients. J Cardiothorac Vasc Anesth 34:2580PubMedPubMedCentralCrossRef

go back to reference Akinosoglou K, Gogos A, Papageorgiou C, Angelopoulos E, Gogos C (2020) Ketamine in COVID-19 patients: Thinking out of the box. J Med Virol. https://doi.org/10.1002/jmv.26681CrossRefPubMedPubMedCentral Akinosoglou K, Gogos A, Papageorgiou C, Angelopoulos E, Gogos C (2020) Ketamine in COVID-19 patients: Thinking out of the box. J Med Virol. https://​doi.​org/​10.​1002/​jmv.​26681CrossRefPubMedPubMedCentral

go back to reference Klepstad P, Maurset A, Moberg ER, Oye I (1990) Evidence of a role for NMDA receptors in pain perception. Eur J Pharmacol 187:513–518PubMedCrossRef Klepstad P, Maurset A, Moberg ER, Oye I (1990) Evidence of a role for NMDA receptors in pain perception. Eur J Pharmacol 187:513–518PubMedCrossRef

go back to reference Hustveit O, Maurset A, Oye I (1995) Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol 77:355–359PubMedCrossRef Hustveit O, Maurset A, Oye I (1995) Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol 77:355–359PubMedCrossRef

go back to reference Kortekaas R, Maguire RP, van Waarde A, Leenders KL, Elsinga PH (2008) Despite irreversible binding, PET tracer [11C]-SA5845 is suitable for imaging of drug competition at sigma receptors—the cases of ketamine and haloperidol. Neurochem Int 53:45–50PubMedCrossRef Kortekaas R, Maguire RP, van Waarde A, Leenders KL, Elsinga PH (2008) Despite irreversible binding, PET tracer [¹¹C]-SA5845 is suitable for imaging of drug competition at sigma receptors—the cases of ketamine and haloperidol. Neurochem Int 53:45–50PubMedCrossRef

go back to reference Leal GC, Bandeira ID, Correia-Melo FS, Telles M, Mello RP, Vieira F, Lima CS, Jesus-Nunes AP, Guerreiro-Costa LNF, Marback RF, Caliman-Fontes AT, Marques BLS, Bezerra MLO, Dias-Neto AL, Silva SS, Sampaio AS, Sanacora G, Turecki G, Loo C, Lacerda ALT, Quarantini LC (2020) Intravenous arketamine for treatment-resistant depression: open-label pilot study. Eur Arch Psychiatry Clin Neurosci. https://doi.org/10.1007/s00406-020-01110-5CrossRefPubMed Leal GC, Bandeira ID, Correia-Melo FS, Telles M, Mello RP, Vieira F, Lima CS, Jesus-Nunes AP, Guerreiro-Costa LNF, Marback RF, Caliman-Fontes AT, Marques BLS, Bezerra MLO, Dias-Neto AL, Silva SS, Sampaio AS, Sanacora G, Turecki G, Loo C, Lacerda ALT, Quarantini LC (2020) Intravenous arketamine for treatment-resistant depression: open-label pilot study. Eur Arch Psychiatry Clin Neurosci. https://​doi.​org/​10.​1007/​s00406-020-01110-5CrossRefPubMed

go back to reference Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA Jr, Gould TD (2018) Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev 70:621–660PubMedPubMedCentralCrossRef Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA Jr, Gould TD (2018) Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev 70:621–660PubMedPubMedCentralCrossRef

go back to reference Yesilkaya UH, Balcioglu YH, Sahin S (2020) Reissuing the sigma receptors for SARS-CoV-2. J Clin Neurosci 80:72–73PubMedPubMedCentralCrossRef Yesilkaya UH, Balcioglu YH, Sahin S (2020) Reissuing the sigma receptors for SARS-CoV-2. J Clin Neurosci 80:72–73PubMedPubMedCentralCrossRef

go back to reference Taquet M, Luciano S, Geddes JR, Harrison P (2020) Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62354 COVID-19 cases in the USA. Lancet Psychiatry. https://doi.org/10.1016/S2215-0366(20)30462-4CrossRefPubMedPubMedCentral Taquet M, Luciano S, Geddes JR, Harrison P (2020) Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62354 COVID-19 cases in the USA. Lancet Psychiatry. https://​doi.​org/​10.​1016/​S2215-0366(20)30462-4CrossRefPubMedPubMedCentral